HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of...
Hence then, the article about akeso s ak157d1 b7 h3 adc cleared for phase i trial in solid tumors adding a third differentiated adc to its pipeline was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline )
Also on site :
- Best-Selling Author’s New Novel, the Latest From the ‘Queen of Twists,’ Ranked Among Amazon’s Most Read Books
- Ticketmaster Cancels Scalped Tickets to Olivia Rodrigo’s “The Unraveled Tour,” and Fans Can Get Them at Face Value
- 1972 Hit Song, Featured in ‘Guardians of the Galaxy’ and ‘Almost Famous,’ Became One of the ‘Greatest Singles of All Time’